

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/55	A1	(11) International Publication Number: WO 99/21561 (43) International Publication Date: 6 May 1999 (06.05.99)
(21) International Application Number: PCT/US98/22777 (22) International Filing Date: 27 October 1998 (27.10.98) (30) Priority Data: 60/062,769 29 October 1997 (29.10.97) US (71)(72) Applicant and Inventor: DAVIS, Bonnie, M. [US/US]; 160 Cold Spring Road, Syosset, NY 11791 (US). (74) Agents: RICHARDS, John; Ladas & Parry, 26 West 61st Street, New York, NY 10023 (US) et al.		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: METHOD FOR TREATMENT OF DISORDERS OF ATTENTION (57) Abstract The present invention relates to the treatment of disorders of attention such as, for example, attention deficit disorder and Tourette's syndrome comprising administering to such a human or animal a safe and effective dose of an active compound selected from the group consisting of galanthamine, lycoramine, O-desmethylgalanthamine, lycoramine, O-desmethylgalanthamine, O-desmethyllycoramine or an ester, ether, carbamate or carbonate of one of these compounds or a pharmaceutically acceptable salt thereof.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

- 1 -

METHOD FOR TREATMENT OF DISORDERS OF ATTENTIONField of the Invention

The present invention relates to the treatment of disorders of attention such as, for example, attention deficit disorder and Tourette's syndrome.

5

Cross Reference to Related Application

This application claims priority from U.S. Provisional Application 60/063,769 filed on October 29, 1997.

Background of the Invention

10 It has been known for a number of years that cholinergic stimulation of the brain causes increases in the state of awareness, for example as described in 1967 by Krnjevic in Anesthesiology Vol. 128 pp 100-104. However, attempts to use cholinomimetic or acetyl choline precursor compounds to treat attentional disorders in humans have had only limited success. Studies using nicotine have shown that it can have some benefit in treating attention deficit problems. Some
15 improvement of attention has been noted in treatments with arecoline, a muscarinic agonist. However, this is a difficult drug to administer and has not been used outside studies.

In recent years a number of acetylcholinesterase inhibitors have been proposed for the treatment of Alzheimer's disease. In particular galanthamine has
20 been proposed for the use in U.S. Patent 4,664,318 and many of its analogues and lycoramine analogues in PCT Publication WO 88/08708. However, as far as I am aware, there has been no suggestion that such compounds should be used for the treatment of disorders of attention. Compounds that have been suggested for use in the treatment for Alzheimer's disease include: aminoacridines such as
25 tetrahydroaminoacridine (THA, also known as tacrine) and velnacrine, which are, however, bedeviled by toxicity problems which are likely to preclude their use in situations other than those where there is no alternative; physostigmine, which cause significant adverse peripheral effects that prevent it from being administered at a dosage level that would result in beneficial results in the brain and galanthamine
30 and some of its analogs. Some reported studies of the use of tacrine in the treatment of Alzheimer's disease have shown some improvement in tasks involving attention in patients treated with tacrine, however, such results have been

inconsistent.

Summary of the Invention

According to the present invention there is provided a treatment for disorders of attention in humans or other animals which comprises administering to
5 said human or animal a safe and effective dose of galanthamine, lycoramine, O-desmethylgalanthamine, O-desmethyllycoramine or an ester, ether, carbamate or carbonate of one of these compounds or a pharmaceutically acceptable salt of any of them.

Ester, ether, carbamate and carbonate groups may be bound to either
10 the 2 or 13 position of the nucleus of the compound or to both of these positions.

Specific Description of the Preferred Embodiments

Galanthamine or lycoramine analogs of use in the present invention may be prepared by use of the methods described for example in PCT Publication WO 88/08708.

15 I have found that there is an improvement in the ability to carry out tasks requiring attention in patients treated with galanthamine at dosage levels in the range of 20 to 50 mg per day. The results obtained are significantly better and more consistent than those achieved using tacrine.


Suitable dosage rates for the present invention can be determined by
20 standard techniques such as identifying potency based on animal studies, determining maximum tolerated dose are administered to subjects who are asked to complete certain standard attentional tasks such as the attentional question on the Mini-Mental State exam and the concentration/distractibility component of the Alzheimer's Disease Assessment Scale.

25 Suitable salts of galanthamine that may be employed in the treatment of the present invention include a variety of pharmaceutically acceptable salts including the hydrobromide and hydrochloride. Suitable esters include those of aliphatic carboxylic acids having from 2 to 6 carbon atoms and those of benzoic or substituted benzoic acids. Suitable carbamates include aliphatic carbamates such as
30 mono and di alkyl carbamates of from 1 to 10 carbon atoms and aryl carbamates such as phenyl or naphthyl and substituted derivatives thereof. Suitable carbonates include aliphatic carbon such as alkyl carbon of from 1 to 10 carbon atoms in each

- 3 -

alkyl groups and aryl carbonates such as phenyl or naphthyl carbamates and substituted derivatives thereof. Suitable ethers include aliphatic ethers such as alkyl ethers of 1 to 6 carbon atoms, aromatic ethers such as phenyl and naphthyl and aryl ethers such as benzyl ethers. In the case of the O-desmethylgalanthamine and
5 O-desmethyllycoramine, such ester, carbamate, carbonate, and ether groups may be bonded either to the 2 or the 13 position of the galanthamine or lycoramine core structure.

Different numbering systems have been used in the literature for galanthamine and lycoramine. The numbering system used in the present
10 application is the following



15

In addition to galanthamine itself, its esters and carbonates and esters and carbonates of 13-desmethylgalanthamine such as the acetyl and other C₁₋₆ alkanoyl esters of 13-desmethylgalanthamine are likely to be of particular use in the
20 present invention. Other useful compounds include O-desmethylgalanthamine, galanthamine 2-methyl carbamate, galanthamine-2-n-butyl carbamate, galanthamine-2- α -naphthyl carbamate, galanthamine-13-n-butyl carbamate, and analogous lower alkyl (C₁₋₈) carbamates.

Compositions suitable for use in treatments according to the invention
25 are typically suitable for oral administration such as tablets, capsules, or lozenges containing from 0.01 to 45 mg. of the active compound depending upon the cavity of the compound. In the case of galanthamine itself such dosage units typically comprise from 5 to 35 mg. of galanthamine or a pharmaceutically acceptable salt. For other compounds such as 13-desmethylgalanthamine-13-isopropyl carbonate and
30 13-desmethyl-13-pivaloate, dosages as low as about 0.5 mg. may be useful. If desired, such oral dosage forms may be sustained dosage formulations in which the particles of the active compound are coated so as to delay release into the blood

- 4 -

stream for example by coating with a pharmaceutically acceptable polymer that is dissolved in gastric juices such as polyvinyl pyrrolidone and then sizing the particles and incorporating specific ratios of particles of particular sizes into a tablet, capsule or lozenge so that particles having different degrees of thickness of coating are released at different times. In the present case, the coating technique will desirably result in most of the active compound being released within twelve hours of administration. Alternative means of application may include for example transdermal patches in which case the objective is to provide administration of a dosage at a rate of 0.001 to 10 mg., per hour.

10 The compounds for use according to the present invention share the same contraindications as other cholinergic drugs. Thus care should be taken before using the present invention on pre-pubertal children and patients who suffer for example from asthma, epilepsy, bradycardia, heart block, hemorrhagic ulcer disease. Furthermore, animal studies have shown that cholinergic drugs may result in
15 overstimulation of the uterus and ovaries in premenopausal women.

- 5 -

C L A I M S

1. A method of treating disorders of attention in humans or other animals which comprises administering to such a human or animal a safe and effective dose of an active compound selected from the group consisting of
5 galanthamine, lycoramine, O-desmethylgalanthamine, lycoramine, O-desmethylgalanthamine, O-desmethyllycoramine or an ester, ether, carbamate or carbonate of one of these compounds or a pharmaceutically acceptable salt thereof.
2. A method as claimed in claim 1, wherein said active compound is used in the form of its hydrobromide or hydrochloride salt.
- 10 3. A method as claimed in claim 1 or claim 2, wherein the active compound is galanthamine.
4. A method as claimed in claim 1 or claim 2, wherein the active compound is O-desmethylgalanthamine.
5. A method as claimed in claim 1 or claim 2, wherein the active
15 compound is selected from the 13-C₁₋₆ alkanoyl esters, 13-benzoyl ester, 13-C₁-C₁₀ mono or dialkyl carbamates, 13-phenyl carbamate, 13- α naphthyl carbamate, 13-C₁-C₁₀ alkyl carbonates, 13-phenyl carbonate, 13-naphthyl carbonate, 13-C₂-C₆ alkyl ethers, 13-phenyl ether, 13-naphthyl ether and 13-benzyl ether of O-desmethylgalanthamine.
- 20 6. A method as claimed in claim 1 or claim 2, wherein the active compound is selected from 2-C₁₋₆ alkanyl esters, 2-benzoyl ester, 2-C₁₋₁₀ mono or dialkyl carbamates, 2-phenyl carbamate, 2- α naphthyl carbamate, 2-C₁₋₁₀ alkyl carbonates, 2-phenyl carbonate, 2-naphthyl carbonate of galanthamine.
7. A method as claimed in claim 1 or claim 2, wherein the active
25 compound is a 2-C₁₋₆ alkyl ether, 2-phenyl ether or 2-benzyl ether of galanthamine.
8. Use of a compound selected from galanthamine, lycoramine, O-desmethylgalanthamine, O-desmethyllycoramine or an ester, ether, carbamate or carbonate of one of these components or a pharmaceutically acceptable salt thereof for the treatment of attention deficit disorders.
- 30 9. A medicine comprising a compound selected from galanthamine, lycoramine, O-desmethylgalanthamine, O-desmethyllycoramine or an ester, ether, carbamate or carbonate of one of these components or a pharmaceutically acceptable

- 6 -

salt thereof for the treatment of attention deficit disorders.

10. Use of a compound selected from galanthamine, lycoramine, O-desmethylgalanthamine, O-desmethyllycoramine, or an ester, ether, carbamate or carbonate thereof or a pharmaceutically acceptable salt of any of these in the
- 5 preparation of a medicament for the treatment of attention deficit disorders.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/22777

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 31/55

US CL : 514/215

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/215

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONEElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)
CAS ONLINE, DERWENT

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,155,226 A (LEE et al.) 13 October 1992, see the entire document.	1-10



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

04 JANUARY 1999

Date of mailing of the international search report

29 JAN 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

ZORREH FAY

Telephone No. (703) 308-1235